Literature DB >> 25248598

Familial pituitary tumors.

Neda Alband1, Márta Korbonits2.   

Abstract

Pituitary adenomas are benign intracranial neoplasms that present a major clinical concern due to hormone overproduction and/or tumor mass effects. The majority of pituitary adenomas occur sporadically; however, familial cases are increasingly being recognized, such as multiple endocrine neoplasia type 1 (MEN1), Carney complex (CNC), and familial isolated pituitary adenoma (FIPA). Familial pituitary tumors appear to differ from their sporadic counterparts both in their genetic basis and in clinical characteristics. Evidence suggests that, especially in MEN1 and FIPA, tumors are more aggressive and affect patients at a younger age, therefore justifying the importance of early diagnosis, while in Carney complex pituitary hyperplasia is common. The genetic alterations responsible for the formation of familial pituitary syndromes include the MEN1 gene, responsible for about 80% of MEN1 cases, the regulatory subunit of the protein kinase A, PRKAR1A, responsible for about 70% of Carney complex cases, and AIP, the gene coding the aryl hydrocarbon receptor interacting protein, responsible for about 20% of FIPA cases. Rarely other genes have also been found responsible for familial pituitary adenoma cases. McCune-Albright syndrome (MAS) also has a genetic origin due to mosaic mutations in the G protein-coupled α subunit coded by the GNAS1 gene. In this chapter, we summarize the genetic and clinical characteristics of these familial pituitary syndromes and MAS.
© 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Carney complex (CNC); McCune–Albright syndrome (MAS); familial isolated pituitary adenomas (FIPA); multiple endocrine neoplasia type 1 (MEN1)

Mesh:

Substances:

Year:  2014        PMID: 25248598     DOI: 10.1016/B978-0-444-59602-4.00023-X

Source DB:  PubMed          Journal:  Handb Clin Neurol        ISSN: 0072-9752


  6 in total

Review 1.  Diagnosis and treatment of refractory pituitary adenomas: a narrative review.

Authors:  Xiaohai Liu; Congxin Dai; Ming Feng; Mingchu Li; Ge Chen; Renzhi Wang
Journal:  Gland Surg       Date:  2021-04

2.  Convergent Identification and Interrogation of Tumor-Intrinsic Factors that Modulate Cancer Immunity In Vivo.

Authors:  Adan Codina; Paul A Renauer; Guangchuan Wang; Ryan D Chow; Jonathan J Park; Hanghui Ye; Kerou Zhang; Matthew B Dong; Brandon Gassaway; Lupeng Ye; Youssef Errami; Li Shen; Alan Chang; Dhanpat Jain; Roy S Herbst; Marcus Bosenberg; Jesse Rinehart; Rong Fan; Sidi Chen
Journal:  Cell Syst       Date:  2019-02-20       Impact factor: 10.304

3.  Frequency of familial pituitary adenoma syndromes among patients with functioning pituitary adenomas in a reference outpatient clinic.

Authors:  N V Marques; L Kasuki; M C Coelho; C H A Lima; L E Wildemberg; M R Gadelha
Journal:  J Endocrinol Invest       Date:  2017-07-08       Impact factor: 4.256

Review 4.  Overview of the 2017 WHO Classification of Pituitary Tumors.

Authors:  Ozgur Mete; M Beatriz Lopes
Journal:  Endocr Pathol       Date:  2017-09       Impact factor: 3.943

5.  Treatment-resistant pediatric giant prolactinoma and multiple endocrine neoplasia type 1.

Authors:  Hoong-Wei Gan; Chloe Bulwer; Owase Jeelani; Michael Alan Levine; Márta Korbonits; Helen Alexandra Spoudeas
Journal:  Int J Pediatr Endocrinol       Date:  2015-07-15

6.  Clinical and Pathological Features of Pheochromocytoma in the Horse: A Multi-Center Retrospective Study of 37 Cases (2007-2014).

Authors:  D Luethy; P Habecker; B Murphy; R Nolen-Walston
Journal:  J Vet Intern Med       Date:  2015-11-27       Impact factor: 3.333

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.